Form 4: 10x Genomics CFO Sells Shares for Tax Obligations

10x Genomics' Chief Financial Officer, Adam Taich, sold 22,315 shares of Class A Common Stock on August 22, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (TXG), reported a sale of company stock.
• The transaction involved the disposition of 22,315 shares of Class A Common Stock.
• The sale occurred on August 22, 2025, at a price of $13.787 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Adam Taich beneficially owns 309,273 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sale to cover taxes) which is a neutral event and does not indicate a change in company fundamentals or executive sentiment towards the company.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

This is a routine insider transaction, common for executives whose compensation includes restricted stock units. It does not reflect a change in company fundamentals or broader industry trends, but rather a standard personal financial event for the executive.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, tax-related sale by an executive, not indicative of a change in company outlook or performance.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, tax-related sale of shares by a company executive, which is a common occurrence with restricted stock unit vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is maintained, pending further substantive company announcements.

Keywords

10x Genomics, TXG, Adam Taich, CFO, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Form 4